HER2-positive Breast Cancer Clinical Trials in New York, New York
12 recruitingNew York, New York
Showing 1–12 of 12 trials
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 2
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07459673
Recruiting
Phase 2
A Study of Surgery and Radiotherapy in People With Breast Cancer
Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center178 enrolled7 locationsNCT07053085
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled53 locationsNCT04893109
Recruiting
Phase 1
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Triple-Negative Breast CancerHER2-positive Breast CancerLeptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute18 enrolled3 locationsNCT05809752
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the Breast+2 more
Dana-Farber Cancer Institute375 enrolled32 locationsNCT04569747
Recruiting
Phase 3
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
HER2-positive Breast Cancer
NRG Oncology1,300 enrolled416 locationsNCT05705401
Recruiting
Phase 2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
MedSIR165 enrolled36 locationsNCT06172127
Recruiting
Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
HER2-low Breast CancerHER2-positive Breast CancerHER2-positive Colorectal Cancer+3 more
Mersana Therapeutics162 enrolled14 locationsNCT05514717